◎ Sugi Atlas

Atlas / Drug / Avelumab

Avelumab

drug
On this page

Also known as BavencioMSB-0010682Msb-0010718cMSB0010682MSB0010718C

Summary

Avelumab (CHEMBL3833373) is an approved antibody (ATC L01FF04); indicated across 71 conditions including cutaneous neuroendocrine carcinoma and neoplasm; with CIViC clinical evidence for 3 variant-indication associations (e.g. CD274 Expression in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF04
  • Indications: 71 conditions
  • Clinical trials: 252
  • Precision-oncology evidence (CIViC): 3 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3833373
NameAvelumab
TypeAntibody
Max phase4
ATCL01FF04

Also known as: Avelumab, Bavencio, MSB-0010682, Msb-0010718c, MSB0010682, MSB0010718C, AVELUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

71 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cutaneous neuroendocrine carcinoma4MONDO:0019210EFO:1001471
neoplasm4MONDO:0005070EFO:0000616
urothelial carcinoma4MONDO:0040679EFO:0008528
neuroendocrine neoplasm4MONDO:0019496EFO:1001901
gastric adenocarcinoma3MONDO:0005036EFO:0000503
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
breast neoplasm3MONDO:0021100EFO:0003869
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
renal cell carcinoma3MONDO:0005086EFO:0000681
squamous cell carcinoma3MONDO:0005096EFO:0000707
renal carcinoma3MONDO:0005206EFO:0002890
ovarian cancer3MONDO:0008170MONDO:0008170
colonic neoplasm3MONDO:0005401MONDO:0021063
clear cell renal carcinoma3MONDO:0005005EFO:0000349
renal cell adenocarcinoma3MONDO:0005549EFO:0005708
gastric neoplasm3MONDO:0021085MONDO:0001056
glioblastoma2MONDO:0018177EFO:0000519
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
Hodgkins lymphoma2MONDO:0004952EFO:0000183
hepatocellular carcinoma2MONDO:0007256EFO:0000182
adenocarcinoma2MONDO:0004970EFO:0000228
lymphoma2MONDO:0005062EFO:0000574
osteosarcoma2MONDO:0009807EFO:0000637
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
rectal cancer2MONDO:0006519EFO:1000657
colorectal carcinoma2MONDO:0024331EFO:1001951
leiomyosarcoma2MONDO:0005058EFO:0000564
small cell lung carcinoma2MONDO:0008433EFO:0000702
plasma cell myeloma2MONDO:0009693EFO:0001378
angiosarcoma2MONDO:0016982EFO:0003968
colorectal neoplasm2MONDO:0005335EFO:0004142
esophageal squamous cell carcinoma2MONDO:0005580EFO:0005922
thymic carcinoma2MONDO:0006451EFO:1000576
thymoma2MONDO:0006456EFO:1000581
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
endometrium neoplasm2MONDO:0021251MONDO:0011962
skin neoplasm2MONDO:0002531MONDO:0002898
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
paraganglioma2MONDO:0000448EFO:1000453
kidney cancer2MONDO:0002367MONDO:0002367
neoplasm of mature B-cells1MONDO:0004949EFO:0000096
acute myeloid leukemia1MONDO:0018874EFO:0000222
mesothelioma1MONDO:0005065EFO:0000588
melanoma1MONDO:0005105EFO:0000756
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
chronic myeloid leukemia1MONDO:0011996EFO:0000339
head and neck cancer1MONDO:0005627EFO:0006859
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
follicular lymphoma1MONDO:0018906MONDO:0018906
glioma1MONDO:0021042MONDO:0100342
central nervous system neoplasm1MONDO:0006130EFO:1000158
chordoma1MONDO:0008978MONDO:0008978
meningioma1MONDO:0016642MONDO:0016642
primary myelofibrosis1MONDO:0009692MONDO:0044903
prostate carcinoma1MONDO:0005159EFO:0001663
uveal melanoma1MONDO:0006486EFO:1000616
pancreatic ductal adenocarcinoma0MONDO:0005184MONDO:0005184

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 252.

Phase distribution

PhaseTrials
PHASE2114
PHASE1/PHASE257
PHASE145
PHASE318
Not specified13
EARLY_PHASE15

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02999087PHASE3ACTIVE_NOT_RECRUITINGRandomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
NCT03271372PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Avelumab in Merkel Cell Cancer
NCT03815643PHASE3ACTIVE_NOT_RECRUITINGAvelumab Program Rollover Study
NCT04637594PHASE3ACTIVE_NOT_RECRUITINGTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT05059522PHASE3ACTIVE_NOT_RECRUITINGContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05092958PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT02395172PHASE3COMPLETEDAvelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
NCT02576574PHASE3COMPLETEDAvelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02580058PHASE3COMPLETEDA Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
NCT02603432PHASE3COMPLETEDA Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
NCT02625610PHASE3COMPLETEDAvelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
NCT02625623PHASE3COMPLETEDAvelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02684006PHASE3COMPLETEDA Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02718417PHASE3TERMINATEDAvelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
NCT02926196PHASE3COMPLETEDAdjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
NCT02951156PHASE3TERMINATEDAvelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT02952586PHASE3TERMINATEDStudy To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
NCT03827044PHASE3TERMINATEDAvelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
NCT02813135PHASE1/PHASE2RECRUITINGEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT02912572PHASE2ACTIVE_NOT_RECRUITINGAvelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT03076554PHASE2ACTIVE_NOT_RECRUITINGA Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
NCT03147287PHASE2ACTIVE_NOT_RECRUITINGPalbociclib After CDK and Endocrine Therapy (PACE)
NCT03217747PHASE1/PHASE2ACTIVE_NOT_RECRUITINGAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
NCT03228667PHASE2ACTIVE_NOT_RECRUITINGQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03260023PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPhase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
NCT03391479PHASE2ACTIVE_NOT_RECRUITINGA Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
NCT03414658PHASE2ACTIVE_NOT_RECRUITINGThe AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT03547973PHASE2RECRUITINGStudy of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03573648PHASE2ACTIVE_NOT_RECRUITINGNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03744793PHASE2ACTIVE_NOT_RECRUITINGPemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
NCT03944941PHASE2ACTIVE_NOT_RECRUITINGAvelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
NCT03964532PHASE1/PHASE2ACTIVE_NOT_RECRUITINGTALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
NCT03971409PHASE2ACTIVE_NOT_RECRUITINGAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT04068194PHASE1/PHASE2ACTIVE_NOT_RECRUITINGTesting the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04071236PHASE1/PHASE2RECRUITINGRadiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT04215146PHASE2ACTIVE_NOT_RECRUITINGA Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
NCT04261855PHASE1/PHASE2ACTIVE_NOT_RECRUITINGTargeted Therapy and Avelumab in Merkel Cell Carcinoma
NCT04266912PHASE1/PHASE2ACTIVE_NOT_RECRUITINGAvelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
NCT04291885PHASE2ACTIVE_NOT_RECRUITINGImmunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
NCT04341181PHASE2RECRUITINGProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Nivolumab + PembrolizumabCIViC BEID1167
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Pembrolizumab + Nivolumab + DurvalumabCIViC BEID4857
CD274 v242Lung Non-small Cell CarcinomaResistanceDurvalumab + Atezolizumab + AvelumabCIViC EEID9695

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem